Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

NCT01818596 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01818596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01818596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 27, 2013
Completion date
July 18, 2018
Enrollment
252 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, hiv infections